RxDoctor Payments Data

Philip Short, MD

Internal Medicine · Zanesville, OHNPI 1598741597

Payments from drug & device makers

$10,948in general payments, 2019–2025

Across 393 payments — averaging $27.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$849
  • Alkermes, Inc.$640
  • Amarin Pharma, Inc.$533
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$10,88099%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,948 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$141,948
Medicare patients
351
Services billed
3,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide75$93,300
EliquisApixaban115$91,942
FarxigaDapagliflozin Propanediol82$85,820
JanuviaSitagliptin Phosphate67$80,681
XareltoRivaroxaban75$70,079
OzempicSemaglutide57$64,810
JardianceEmpagliflozin71$57,063
ProliaDenosumab23$39,945
TradjentaLinagliptin19$17,717
VascepaIcosapent Ethyl30$12,188
Breo ElliptaFluticasone/Vilanterol30$11,280
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$10,224
LinzessLinaclotide14$9,572
Tresiba Flextouch U-200Insulin Degludec13$7,764
Potassium Chloride275$6,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$849$93,30075 claims
PfizerEliquis$206$91,942115 claims
AstraZenecaFarxiga$1,387$85,82082 claims
MerckJanuvia$56$80,68167 claims
Boehringer IngelheimJardiance, Tradjenta$12$74,77990 claims
Johnson & JohnsonXarelto$253$70,07975 claims
Novo NordiskOzempic$484$64,81057 claims
AmgenProlia$1,574$39,94523 claims
GSKBreo Ellipta, Anoro Ellipta$269$17,35043 claims
AbbVieLinzess, Synthroid$1,729$15,451114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Zanesville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →